Anixa Reports Encouraging CAR-T Efficacy, Breast Cancer Vaccine Phase 1 Success, and Extended Cash Runway
ANIX is trading near its 52-week low of $2.35 (0.4% above the low).
Summary
Anixa Biosciences reported positive clinical progress for its CAR-T and breast cancer vaccine programs, along with a stable financial outlook and an expanded vaccine pipeline.
Key Events · Product Development and Regulatory · ANIX
-
Encouraging CAR-T Efficacy in Ovarian Cancer
The Phase 1 trial for lira-cel (CAR-T) in ovarian cancer showed anecdotal signs of efficacy, including T cell infiltration, tumor necrosis, and extended survival in multiple patients, with some living significantly beyond their expected median survival.
-
Breast Cancer Vaccine Phase 1 Completed with Positive Results
The Phase 1 clinical trial for the breast cancer vaccine successfully met all primary endpoints, demonstrating safety and immune responses in 74% of subjects. The company is now preparing to initiate a Phase 2 trial.
-
Extended Cash Runway
The company reaffirmed its belief that existing cash, cash equivalents, and short-term investments of $13.686 million (as of April 30, 2026) will fund operations for 'significantly longer than 12 months'.
-
ATM Offering Provides Capital
Anixa raised $2.87 million, net of expenses, through an at-the-market (ATM) equity offering of 887,134 shares during the six months ended April 30, 2026, with approximately $97 million remaining available under the program.
Analysis · ANIX · Life Sciences
This quarterly report provides significant positive updates on Anixa's clinical pipeline and financial stability. The detailed anecdotal efficacy and extended survival observations from the CAR-T trial for ovarian cancer are highly encouraging for a patient population with limited options. The successful completion of Phase 1 for the breast cancer vaccine, meeting all primary endpoints and paving the way for a Phase 2 trial, marks a critical advancement. These clinical milestones, coupled with a reaffirmed cash runway of 'significantly longer than 12 months' and a new vaccine development agreement, are very important for a clinical-stage biotech, especially with the stock trading near its 52-week low.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANIX was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.8M. The 52-week trading range was $2.35 to $5.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.